Eupraxia Pharmaceuticals Says Phase 2b Trial in Eosinophilic Esophagitis Meets Enrollment Target

08:46 AM EDT, 10/15/2026 (MT Newswires) -- Eupraxia Pharmaceuticals (EPRX) said Thursday that it has reached its target enrollment of 120 patients for a phase 2b study of EP-104GI in eosinophilic esophagitis. The company said it has treated its 120th patient in the placebo-controlled trial, which is evaluating doses of 120mg and 160mg of EP-104GI. Interim results are expected in December, Eupraxia said. Eosinophilic esophagitis is an inflammatory-mediated disease, which creates pain and difficulty for patients when swallowing food. Shares of Eupraxia were down 4.4% pre-bell Thursday.